Table 2.

Analysis of factors affecting HbA1c variations at 3 months after the start of therapy (age ≥ 65 years)

Variables	Univariate analysis					Multivariate analysis
	Partial regression coefficient	Standard partial regression coefficient	Lower limit	Upper limit	p value*	Partial regression coefficient	Standard partial regression coefficient	Lower limit	Upper limit	p value*
Age	−0.001	−0.007	−0.014	0.012	0.907
Sex (male)	−0.048	−0.033	−0.213	0.117	0.567
Duration of diabetes	0.000	0.012	−0.001	0.001	0.837
HbA1c	−0.476	−0.572	−0.552	−0.399	0.000*	−0.481	−0.581	−0.561	−0.401	0.000*
Systolic blood pressure	0.001	0.016	−0.005	0.006	0.777
Smoking	−0.153	−0.077	−0.376	0.071	0.180	−0.080	−0.042	−0.266	0.105	0.393
Alcohol consumption	0.078	0.052	−0.093	0.249	0.370
Group with diet/exercise therapy	0.033	0.020	−0.147	0.212	0.721
Group with SU (excluding multidrug therapy)	−0.036	−0.021	−0.229	0.158	0.717
Insulin resistance improving drug (excluding multidrug therapy)	−0.143	−0.073	−0.361	0.074	0.196	−0.173	−0.093	−0.349	0.004	0.055
BMI	−0.014	−0.063	−0.038	0.011	0.273
Waist circumference	−0.003	−0.040	−0.013	0.007	0.573
Triglyceride	0.001	0.095	0.000	0.002	0.104	0.001	0.128	0.000	0.002	0.010*
LDL-C	−0.001	−0.026	−0.004	0.002	0.661
eGFR	−0.001	−0.030	−0.006	0.004	0.614
Antihypertensive drug	0.108	0.073	−0.057	0.274	0.198	−0.056	−0.038	−0.196	0.085	0.437
Antihyperlipidemic drug	0.036	0.025	−0.126	0.199	0.660

Factors with p < 0.2 in the single regression analysis were extracted, and multiple regression analysis was performed using these factors

Patients with higher baseline HbA1c levels were likely to show large decreases in HbA1c levels, while patients with higher triglyceride levels were unlikely to do so

* p < 0.05